Basilea Pharmaceutica AG Stock Xetra
Stocks
PK5
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 643M 795M 691M 591M 1.12B 75.9B 1.13B 7.58B 2.98B 37.79B 2.99B 2.92B 127B | P/E 2026 * |
13.8x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 491M 607M 528M 451M 851M 57.94B 865M 5.79B 2.27B 28.84B 2.28B 2.23B 96.72B | EV / Sales 2026 * |
1.87x | EV / Sales 2027 * | 1.61x |
| Free-Float |
91.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 795M | |
| -1.40% | +2.59% | -1.71% | +11.28% | 48.53B | |
| -2.41% | -0.90% | +411.96% | +495.33% | 39.87B | |
| -1.16% | +12.96% | +28.81% | +7.25% | 38.68B | |
| -1.88% | -3.03% | +5.69% | +53.00% | 35.13B | |
| -1.74% | +5.12% | +14.44% | +41.77% | 29.79B | |
| -0.21% | -4.04% | +36.40% | +125.75% | 16.11B | |
| -2.85% | -3.92% | - | - | 16.08B | |
| -0.64% | +2.65% | +3.40% | +13.11% | 13.61B | |
| -1.19% | -1.32% | -1.73% | -34.37% | 12.62B | |
| Average | -1.35% | +1.05% | +62.16% | +89.14% | 27.82B | |
| Weighted average by Cap. | -1.59% | +2.03% | +79.78% | +108.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 263M 325M 282M 241M 456M 31.02B 463M 3.1B 1.22B 15.44B 1.22B 1.19B 51.78B | 267M 331M 287M 246M 464M 31.56B 471M 3.15B 1.24B 15.71B 1.24B 1.21B 52.68B |
| Net income | 51.57M 63.73M 55.4M 47.35M 89.41M 6.08B 90.79M 608M 239M 3.03B 239M 234M 10.16B | 39.24M 48.5M 42.16M 36.03M 68.03M 4.63B 69.09M 463M 182M 2.3B 182M 178M 7.73B |
| Net Debt | -152M -188M -164M -140M -264M -17.96B -268M -1.79B -704M -8.94B -707M -691M -29.99B | -213M -263M -228M -195M -369M -25.08B -374M -2.51B -983M -12.49B -987M -965M -41.87B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
